Pfizer Prevails In COX-2 Patent Case
This article was originally published in The Pink Sheet Daily
Executive Summary
A University of Rochester patent claiming the use of COX-2 inhibitors to treat inflammation is invalid, a federal appeals court said in a ruling for Pfizer